[Is the frequency of hemolytic uremic syndrome as a complication of gemcitabine underestimated? The role of systematic screening]

Gastroenterol Clin Biol. 2006 Feb;30(2):332-4. doi: 10.1016/s0399-8320(06)73184-0.
[Article in French]
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Antimetabolites, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / adverse effects*
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives*
  • Female
  • Gemcitabine
  • Hemolytic-Uremic Syndrome / chemically induced*
  • Hemolytic-Uremic Syndrome / diagnosis
  • Humans
  • Male
  • Mass Screening
  • Mesothelioma / drug therapy
  • Middle Aged
  • Pancreatic Neoplasms / drug therapy
  • Peritoneal Neoplasms / drug therapy

Substances

  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Gemcitabine